New research continues to reinforce the efficacy of RESPeRATE while
highlighting interest in the device by the scientific community
BERLIN and NEW YORK, June 16 /PRNewswire/ -- European Society of Hypertension -- Booth # 21, Hall 15.1 -- InterCure Ltd., a medical device company publicly traded on the Tel-Aviv Stock Exchange (TASE: INCR), today announced the findings of new studies and analysis highlighting RESPeRATE -- the only medical device cleared by the FDA and CE-approved for the treatment of hypertension. Five posters will be presented at the European Society of Hypertension meeting (ESH) in Berlin beginning June 14, 2008. Two of the five posters focus on RESPeRATE's effect on blood pressure as measured by 24-hour ambulatory blood pressure monitoring. Three of the posters also present new findings in the emerging field of obtaining vascular risk parameters from blood pressure measurements. The fifth poster demonstrates the benefits of RESPeRATE in patients with chronic heart failure.
"InterCure is making great strides within the European marketplace and has received a tremendous response from both the scientific and consumer communities," says Erez Gavish, president and CEO of InterCure. "The continued clinical interest is producing a constant drumbeat of validation for RESPeRATE, paving the path for the successful charge into retail outlets in Europe and the U.S. and building on the more than 100,000 hypertension sufferers who have already adopted RESPeRATE as a treatment for their hypertension."
Results of the findings related to RESPeRATE are being presented as
posters at ESH and are as follows:
-- PS26/WED/05 -- A study performed in Turkey, led by Prof. Erdine,
Department of Cardiology, Istanbul University, demonstrated that the
RESPeRATE device provides daytime and nighttime blood pressure
reductions as measured by 24-hour ambulatory monitoring. The study
also demonstrated that patients were compliant with the device and that
no adverse side effects were reported.
-- PS33/THU/01 -- Pooled results from two separate studies led by Profs.
Rosenthal and the Erdine study (above), utilizing 24-hour ambulatory
blood pressure monitoring demonstrated that RESPeRATE benefits
uncontrolled-hypertension sufferers. The analysis demonstrated a
clinically significant blood pressure reduction throughout both daytime
and nighttime. RESPeRATE was also found to independently reduce high
values of a risk-associated arterial property (S-D slope/AASI) derived
from the relationship between systolic and diastolic pressures.
-- PS34/MON/08 -- Data analysis led by Dr. Benjamin Gavish, chief
scientific officer, InterCure, Ltd., of a study performed in Italy,
conducted by Prof. Gianfranco Parati, explored, for the first time, the
linear relationships between systolic and diastolic blood pressure from
beat-to-beat measurements. The derived risk-related parameters (S-D
slope and AASI) are acutely influenced by breathing patterns and neck
-- PS34/MON/18 -- An Israeli study, conducted by Dr. Iddo Ben-Dov and
Prof. Michael Burzstyn from Hadassah Medical Center, and Dr. Benjamin
Gavish, concluded that the ratio of systolic to diastolic blood
pressure variability is shown to be a blood pressure-independent
predictor of mortality, associated with the linear relationship between
systolic and diastolic pressures.
-- PS18/WED/58 -- An Italian, randomized controlled study, led by Prof. G.
Parati from the University of Milan-Bicocca concluded that device-
guided paced breathing at home is feasible and improves prognostically
relevant clinical and instrumental parameters in heart failure
patients. It is recommended as an additional long-term treatment
program for these patients.
About InterCure Ltd. and RESPeRATE
InterCure Ltd. (Tel-Aviv Stock Exchange: INCR) is disrupting the $42 billion hypertension industry with the world's first FDA-cleared, OTC blood pressure treatment device, RESPeRATE(R) (http://www.resperate.com). In a market where seven out of 10 hypertensives are NOT controlled despite the availability of more than 100 blood pressure medications, RESPeRATE provides an effective non-drug therapy with no side effects.
RESPeRATE has gained widespread support of hypertension specialists and has secured regulatory clearance in most key international markets. Ten separate clinical studies have proven the device's efficacy and safety, and RESPeRATE is now featured in more than 20 popular and professional text books.
With more than 100,000 units sold, thousands of supportive clinicians worldwide and one of the world's most popular hypertension websites, InterCure is now introducing RESPeRATE into retail pharmacies to increase access to hypertension sufferers.
InterCure has an exciting product pipeline based on its broadly-patented "Device-Guided Breathing" technology platform. This technology enables a systematic reduction in sympathetic outflow of the autonomic nervous system, one of the key underlying causes of cardiovascular disease, insomnia and several other medical conditions.
This news release may contain forward-looking statements that are based
on the Company's current beliefs and assumptions and on information
currently available to its management. Forward-looking statements involve
known and unknown risks, uncertainties and other factors that may cause the
Company's actual results, performance or achievements to be materially
different from any future results, performance or achievements expressed or
implied by the forward-looking statements. As a result of these risks,
uncertainties and other factors, readers are cautioned not to place undue
reliance on any forward-looking statements included in this press release.
These forward- looking statements represent beliefs and assumptions only as
of the date of this news release, and the Company assumes no obligation to
update these forward-looking statements publicly, even if new information
becomes available in the future.
Lisa Mokaba Brian Packard
Schwartz Communications InterCure, Inc.
+1-781-684-0770 +1-646-652-5800 x.7134
|SOURCE InterCure, Inc.|
Copyright©2008 PR Newswire.
All rights reserved